Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carteolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 8/20 | 1.00 |
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 1.00 |
| ▸ | ADRB3 known ✓ | P13945 | 2/20 | 0.62 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carteolol SCHEMBL24811 | 1.00 | ADRB1 (1.00) | ADRB1ADRB2HTR1AOPRK1SLC6A4 | |
| Carteolol SCHEMBL2549082 | 1.00 | ADRB1 (1.00) | ADRB1ADRB2HTR1AOPRK1SLC6A4 | |
| Carteolol SCHEMBL29908301 | 1.00 | ADRB1 (1.00) | ADRB1ADRB2HTR1AOPRK1SLC6A4 | |
| Carteolol SCHEMBL30872857 | 1.00 | ADRB1 (1.00) | ADRB1ADRB2HTR1AOPRK1SLC6A4 | |
| Carteolol SCHEMBL146637 | 1.00 | ADRB1 (1.00) | ADRB1ADRB2HTR1AOPRK1SLC6A4 | |
| Carteolol SCHEMBL41380 | 0.99 | ADRB2 (0.98) | ADRB1ADRB2HTR1AOPRK1SLC6A4 | |
| Carteolol SCHEMBL26664802 | 0.99 | ADRB1 (0.98) | ADRB1ADRB2HTR1AOPRK1SLC6A4 | |
| Carteolol SCHEMBL41382 | 0.99 | ADRB2 (0.98) | ADRB1ADRB2HTR1AOPRK1SLC6A4 | |
| Carteolol SCHEMBL29506901 | 0.99 | ADRB2 (0.98) | ADRB1ADRB2HTR1AOPRK1SLC6A4 | |
| Carteolol SCHEMBL26664799 | 0.99 | ADRB1 (0.98) | ADRB1ADRB2HTR1AOPRK1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 20064 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6335335-B1 | — | — | None | — | — | US | claimed |
| EP-4727545-A2 | COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS | Neurawell Therapeutics (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20260076953-A1 | METHODS OF DIAGNOSING AND TREATING ADHD IN BIOMARKER POSITIVE SUBJECTS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-03-19 | — | — | US | claimed |
| US-20260048096-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-02-19 | — | — | US | claimed |
| EP-4691568-A2 | LOW-DOSE BRIMONIDINE COMBINATIONS AND USES THEREOF | Eye Therapies, LLC (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260027105-A1 | COMPOUND MEDICINE COMPOSITION FOR TREATING GLAUCOMA AND USE OF SAME | SHENYANG PHARMACEUTICAL UNIVERSITY (CN) | 2026-01-29 | — | — | US | claimed |
| US-20260000635-A1 | THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING FP AGONIST AND ß BLOCKER | ONO PHARMACEUTICAL CO., LTD. (JP) | 2026-01-01 | — | — | US | claimed |
| US-20250388639-A1 | Therapeutic applications based on the inhibition of G Protein-Coupled Receptor 182 (GPR182) | MAX PLANCK GESELLSCHAFT (DE) | 2025-12-25 | — | — | US | claimed |
| EP-0073819-A4 | NASAL ADMINISTRATION OF BETA-BLOCKERS AND DOSAGE FORMS THEREFOR. | UNIV KENTUCKY RES FOUND (US) | 1984-11-16 | — | — | EP | claimed |
| US-4468391-A | Combination of β-adrenoceptor antagonists and anxiolytic agents | AYERST, MCKENNA & HARRISON, INC. (CA) | 1984-08-28 | — | — | US | claimed |
| US-4428883-A | NASAL OINTMENTS OR GELS | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1984-01-31 | — | — | US | claimed |
| EP-0098113-A1 | A combination of beta-adrenoceptor antagonists and anxiolytic agents | AYERST, MCKENNA AND HARRISON INC. (CA) | 1984-01-11 | — | — | EP | claimed |
| EP-0073819-A1 | NASAL ADMINISTRATION OF BETA-BLOCKERS AND DOSAGE FORMS THEREFOR. | UNIV KENTUCKY RES FOUND (US) | 1983-03-16 | — | — | EP | claimed |
| EP-0069385-A2 | Use of eucalyptol for enhancing skin permeation of bioaffecting agents | MERCK & CO. INC. (US) | 1983-01-12 | — | — | EP | claimed |
| WO-1982003009-A1 | NASAL ADMINISTRATION OF BETA-BLOCKERS AND DOSAGE FORMS THEREFOR | UNIV KENTUCKY RES FOUND (US) | 1982-09-16 | — | — | WO | claimed |
| EP-0037622-A2 | Drug delivery insert for controlled ocular therapy | ALZA CORPORATION (US) | 1981-10-14 | — | — | EP | claimed |
| EP-0036138-A2 | Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide | MERCK & CO. INC. (US) | 1981-09-23 | — | — | EP | claimed |
| US-4281654-A | Drug delivery system for controlled ocular therapy | ALZA CORPORATION (US) | 1981-08-04 | — | — | US | claimed |